GeoVax Labs, Inc. (Nasdaq: GOVX) today emphasized how its recently presented Phase 2 clinical data for GEO-CM04S1 align with the new Infectious Diseases Society of America (IDSA) guidelines prioritizing vaccination for immunocompromised individuals. The IDSA guidance, issued October 17, 2025, concluded that existing COVID-19 vaccines provide only moderate and short-lived protection for immunocompromised patients, with effectiveness against hospitalization ranging from 33% to 56% and waning within two months. The panel called for new vaccine strategies tailored to vulnerable populations, including cancer patients, transplant recipients, and individuals receiving immunosuppressive therapies.
“Immunocompromised Americans are not a niche,” said David A. Dodd, Chairman & CEO of GeoVax. “They are cancer patients, transplant recipients, people with autoimmune disease, and those living with HIV - one in eight adults. They include family members, colleagues and neighbors. Yet mainstream vaccine approaches, heavily centered on mRNA, continue to leave them without durable protection. The new IDSA guidelines reinforce the urgent need for alternatives like GeoVax’s GEO-CM04S1.”
At the World Vaccine Congress Europe 2025 in Amsterdam, GeoVax presented new interim data from ongoing Phase 2 studies of GEO-CM04S1, the company’s multi-antigen, MVA-based COVID-19 vaccine designed for immunocompromised populations. Key findings included robust T-cell responses to both Spike and Nucleocapsid antigens, exceeding responses seen with mRNA boosters; broad, cross-variant immunity, including activity against Omicron subvariants; and a favorable safety profile, with only mild-to-moderate adverse events such as injection site reactions, fatigue, and myalgia; no vaccine-related serious adverse events reported. In patients with hematologic malignancies post-transplant or CAR-T therapy, breakthrough infections were mild-to-moderate, underscoring the vaccine’s protective potential in highly vulnerable groups.
“These results, together with IDSA’s updated guidance, reinforce the critical need for vaccine platforms that move beyond antibody-only strategies,” said Dodd. “GEO-CM04S1 is designed to provide balanced immunity - antibodies plus durable T-cell responses - which are essential for the immunocompromised patients who remain most vulnerable despite existing vaccination campaigns. The convergence of these guidelines and our clinical findings underscores GEO-CM04S1’s potential to address one of the most critical gaps in COVID-19 prevention.”
GeoVax’s GEO-CM04S1 is a multi-antigen, Modified Vaccinia Ankara (MVA)-based COVID-19 vaccine designed to elicit both antibody and T-cell immune responses. This dual-pathway activation is particularly important for patients who often fail to mount sufficient antibody responses with current mRNA vaccines, including cancer patients on chemotherapy, transplant recipients, and those receiving immunosuppressive therapies. Key features include multi-antigen breadth (Spike + Nucleocapsid proteins) to provide broader immunologic coverage and durable cellular immunity. Ongoing trials include Phase 2 studies as a primary vaccine for immunocompromised individuals and as a booster for patients with chronic lymphocytic leukemia.
While mRNA vaccines were pivotal in the early pandemic response, their limitations in durability, breadth, and performance in immunocompromised populations highlight the risks of relying on a single platform. “Protecting the over 40 million immunocompromised Americans is both a moral imperative and a national security necessity,” added Dodd. “With positive clinical data and alignment with IDSA guidance, GeoVax is delivering a differentiated vaccine platform designed to serve those who need it most.”
